BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6145565)

  • 1. The disposition of the new anthracycline antibiotic, menogarol, in mice.
    Dodion P; Chang BK; Egorin MJ; Olman EA; Engisch KL; Bachur NR
    Drug Metab Dispos; 1984; 12(3):365-70. PubMed ID: 6145565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
    Dodion P; Egorin MJ; Engisch KL; Bachur NR
    Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
    Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
    Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
    Adams WJ; McGovren JP; Dalm EA; Brewer JE; Hosley JD
    Cancer Res; 1989 Nov; 49(22):6328-36. PubMed ID: 2529962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture.
    Bhuyan BK; Blowers CL; Crampton SL; Shugars KD
    Cancer Res; 1981 Jan; 41(1):18-24. PubMed ID: 7448758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the anthracycline agent, 7-con-O-methylnogarol (7-OMEN), administered orally to mice bearing P388 or L1210 leukemia.
    McGovren JP
    Cancer Treat Rep; 1980; 64(4-5):727-9. PubMed ID: 6448690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The murine metabolism and disposition of marcellomycin.
    Dodion P; Egorin MJ; Tamburini JM; Riggs CE; Bachur NR
    Drug Metab Dispos; 1984; 12(2):209-16. PubMed ID: 6144487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
    Ratain MJ; Schilsky RL
    Cancer Res; 1986 Sep; 46(9):4874. PubMed ID: 2942243
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitation of anthracycline antitumor agent menogarol in plasma using liquid chromatography with fluorescence detection.
    McGovren JP; Hamilton RD; Adams WJ; Pratt EA
    Anal Chem; 1984 Aug; 56(9):1587-90. PubMed ID: 6237597
    [No Abstract]   [Full Text] [Related]  

  • 10. Cellular pharmacology of 7(R)-O-methylnogarol: a new anticancer agent.
    Egorin MJ; Clawson RE; Cohen JL; Ross LA; Bachur NR
    J Pharmacol Exp Ther; 1979 Aug; 210(2):229-36. PubMed ID: 458629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.
    Levey BA; Ruiz E; Rogerson B; Lehotay DC; Levey GS
    Cancer Treat Rep; 1980; 64(10-11):1127-8. PubMed ID: 6109566
    [No Abstract]   [Full Text] [Related]  

  • 12. Intracellular uptake of 7-con-o-methylnogarol and adriamycin by cells in culture and its relationship to cell survival.
    Bhuyan BK; McGovren JP; Crampton SL
    Cancer Res; 1981 Mar; 41(3):882-7. PubMed ID: 6450639
    [No Abstract]   [Full Text] [Related]  

  • 13. Menogaril: a new anthracycline agent entering clinical trials.
    McGovren JP; Nelson KG; Lassus M; Cradock JC; Plowman J; Christopher JP
    Invest New Drugs; 1984; 2(4):359-67. PubMed ID: 6239835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.
    Zanette ML; Tirelli U; Sorio R; Zadro D; Figoli F; Monfardini S; D'Incalci M
    Cancer Chemother Pharmacol; 1987; 20(1):67-70. PubMed ID: 2957106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells.
    Adams EG; Crampton SL; Bhuyan BK
    Cancer Res; 1981 Dec; 41(12 Pt 1):4981-7. PubMed ID: 6458356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
    Spiegel JF; Egorin MJ; Collins JM; Lerner BD; Bachur NR
    Drug Metab Dispos; 1983; 11(1):41-6. PubMed ID: 6132794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
    Long HJ; Powis G; Schutt AJ; Moertel CG
    Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 7-R-O-methylnogarol (menogaril) on L1210 cell progression in vitro and in vivo.
    Adams EG; Bhuyan BK
    Cancer Res; 1986 Dec; 46(12 Pt 1):6125-30. PubMed ID: 2946401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
    Klecker RW; Jamis-Dow CA; Egorin MJ; Erkmen K; Parker RJ; Stevens R; Collins JM
    Drug Metab Dispos; 1994; 22(2):254-8. PubMed ID: 7912177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.